{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:44:47Z","timestamp":1792698287893,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.chest.2024.04.025","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T22:59:05Z","timestamp":1717023545000},"page":"778-792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Pulmonary Hypertension in Interstitial Lung Disease"],"prefix":"10.1016","volume":"166","author":[{"given":"Hui Li","family":"Ang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2120-0792","authenticated-orcid":false,"given":"Roseanne Kimberley","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7898-9641","authenticated-orcid":false,"given":"Hann Hsiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9342","authenticated-orcid":false,"given":"Yet Hong","family":"Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2024.04.025_bib1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00171307","article-title":"Pulmonary hypertension in interstitial lung disease","volume":"31","author":"Behr","year":"2008","journal-title":"Eur Respir J"},{"issue":"129","key":"10.1016\/j.chest.2024.04.025_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1183\/09059180.00002713","article-title":"Pulmonary hypertension in chronic interstitial lung diseases","volume":"22","author":"Caminati","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"143","key":"10.1016\/j.chest.2024.04.025_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0053-2016","article-title":"Pulmonary vascular and cardiac impairment in interstitial lung disease","volume":"26","author":"Panagiotou","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE Trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2024.04.025_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis","volume":"158","author":"Nathan","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12127","article-title":"Clinical significance of pulmonary hypertension in interstitial lung disease: a consensus statement from the Pulmonary Vascular Research Institute\u2019s innovative drug development initiative-group 3 pulmonary hypertension","volume":"12","author":"Nikkho","year":"2022","journal-title":"Pulm Circ"},{"issue":"5","key":"10.1016\/j.chest.2024.04.025_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2019.01.035","article-title":"A\u00a0prospective evaluation of the diagnostic accuracy of the physical examination for pulmonary hypertension","volume":"155","author":"Braganza","year":"2019","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2024.04.025_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement","volume":"65","author":"Hoy","year":"2012","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.chest.2024.04.025_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2024.04.025_bib11","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 6.4","article-title":"Chapter 25: Assessing risk of bias in a non-randomized study","author":"Sterne","year":"2023"},{"key":"10.1016\/j.chest.2024.04.025_bib12","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 6.4","article-title":"Chapter 8: Assessing risk of bias in a randomized trial","author":"Higgins","year":"2023"},{"key":"10.1016\/j.chest.2024.04.025_bib13","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 6.3","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2022"},{"issue":"suppl 61","key":"10.1016\/j.chest.2024.04.025_bib14","first-page":"OA313","article-title":"Effects of mean pulmonary arterial pressure and supplemental oxygen on exercise capacity in IPF patients with exercise-induced hypoxemia","volume":"50","author":"Arizono","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00408-009-9209-8","article-title":"Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis","volume":"188","author":"Jackson","year":"2010","journal-title":"Lung"},{"issue":"9","key":"10.1016\/j.chest.2024.04.025_bib18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2024.04.025_bib20","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs\u00a0rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib21","first-page":"200","article-title":"Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study","volume":"17","author":"Tanaka","year":"2017","journal-title":"BMC Polm"},{"issue":"9","key":"10.1016\/j.chest.2024.04.025_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ehj.2013.03.004","article-title":"Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension","volume":"66","author":"Salem","year":"2014","journal-title":"Egyptian Heart Journal"},{"issue":"10","key":"10.1016\/j.chest.2024.04.025_bib25","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3899\/jrheum.110499","article-title":"Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study","volume":"38","author":"Furuya","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2024.04.025_bib26","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s10554-020-01859-9","article-title":"Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography","volume":"36","author":"Huitema","year":"2020","journal-title":"Int J Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1183\/13993003.01319-2015","article-title":"Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis","volume":"47","author":"Huitema","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2024.04.025_bib28","first-page":"584","article-title":"Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis","volume":"55","author":"Modrykamien","year":"2010","journal-title":"Respir Care"},{"issue":"4","key":"10.1016\/j.chest.2024.04.025_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keh067","article-title":"Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis","volume":"43","author":"Mukerjee","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib30","first-page":"172","article-title":"Failure of noninvasive prediction of pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"75","author":"Salajka","year":"2011","journal-title":"Monaldi Arch Chest Dis"},{"issue":"4","key":"10.1016\/j.chest.2024.04.025_bib31","first-page":"CR177","article-title":"Doppler echocardiography-right heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension","volume":"14","author":"Swanson","year":"2008","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1590\/1516-3180.2015.00701207","article-title":"Usefulness of the second heart sound for predicting pulmonary hypertension in patients with interstitial lung disease","volume":"134","author":"Cobra","year":"2016","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.chest.2024.04.025_bib33","first-page":"A1546","article-title":"Prevalence of pulmonary hypertension in newly diagnosed patients with idiopathic pulmonary fibrosis (IPF) enrolled in the IPF-pro registry","volume":"195","author":"Sheth","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib34","first-page":"259","article-title":"Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients","volume":"13","author":"Wu","year":"2019","journal-title":"Fronteras en Medicina"},{"issue":"12","key":"10.1016\/j.chest.2024.04.025_bib35","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.3390\/jcm9123828","article-title":"Predictors of mortality in patients with interstitial lung disease-associated pulmonary hypertension","volume":"9","author":"Alhamad","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.chest.2024.04.025_bib36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.rmed.2012.02.015","article-title":"Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6\u00a0min walk test","volume":"106","author":"Andersen","year":"2012","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.chest.2024.04.025_bib37","first-page":"695","article-title":"Predictors of survival in idiopathic interstitial pneumonia","volume":"14","author":"Carbone","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1378\/chest.06-1466","article-title":"Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis","volume":"131","author":"Hamada","year":"2007","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00408-011-9361-9","article-title":"Pulmonary hypertension in chronic hypersensitivity pneumonitis","volume":"190","author":"Koschel","year":"2012","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.chest.2024.04.025_bib40","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1378\/chest.128.4.2393","article-title":"Pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"128","author":"Nadrous","year":"2005","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2024.04.025_bib41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3906\/sag-1802-196","article-title":"Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)","volume":"48","author":"Ozturk","year":"2018","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.chest.2024.04.025_bib42","article-title":"Does pulmonary hypertension preclude or impact outcomes in single lung transplantations for pulmonary fibrosis in the older recipients","volume":"1","author":"Reddy","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.rmed.2008.11.012","article-title":"Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis","volume":"103","author":"Song","year":"2009","journal-title":"Respir Med"},{"issue":"suppl 2","key":"10.1016\/j.chest.2024.04.025_bib44","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/annrheumdis-2016-eular.2139","article-title":"Pulmonary arterial hypertension as a risk factor for mortality in connective tissue disease with biopsy proven interstitial lung disease","volume":"75","author":"Svensson","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"19-20","key":"10.1016\/j.chest.2024.04.025_bib45","first-page":"766","article-title":"Pulmonary hypertension in hypersensitivity pneumonitis","volume":"128","author":"Tornyos","year":"2016","journal-title":"Wien Klin Wochenschr"},{"issue":"4 suppl","key":"10.1016\/j.chest.2024.04.025_bib46","doi-asserted-by":"crossref","first-page":"A1076","DOI":"10.1016\/j.chest.2020.08.991","article-title":"Systemic sclerosis-associated precapillary pulmonary hypertension with and without interstitial lung disease: observations from a single referral center cohort","volume":"158","author":"Ahmad","year":"2020","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.chest.2024.04.025_bib47","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3899\/jrheum.140156","article-title":"Lung function and survival in systemic sclerosis interstitial lung disease","volume":"41","author":"Ahmed","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib48","doi-asserted-by":"crossref","first-page":"04","DOI":"10.1183\/23120541.00124-2017","article-title":"A\u00a0stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease","volume":"4","author":"Bax","year":"2018","journal-title":"ERJ Open Res"},{"issue":"8","key":"10.1016\/j.chest.2024.04.025_bib49","doi-asserted-by":"crossref","first-page":"929","DOI":"10.5858\/arpa.2017-0463-OA","article-title":"Morphometric study of pulmonary arterial changes in pulmonary Langerhans cell histiocytosis","volume":"142","author":"Bois","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/039463201202500314","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress","volume":"25","author":"Castria","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"10","key":"10.1016\/j.chest.2024.04.025_bib51","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4065\/79.10.1269","article-title":"Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis","volume":"79","author":"Chaowalit","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.chest.2024.04.025_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib53","doi-asserted-by":"crossref","first-page":"07","DOI":"10.1183\/13993003.00545-2018","article-title":"Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia","volume":"52","author":"King","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2024.04.025_bib54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5664\/jcsm.2758","article-title":"Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis","volume":"9","author":"Kolilekas","year":"2013","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib55","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1378\/chest.129.3.746","article-title":"Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis","volume":"129","author":"Lettieri","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.08-2306","article-title":"Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension","volume":"136","author":"Mejia","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2024.04.025_bib57","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00408-015-9794-7","article-title":"Ten-year survival in patients with idiopathic pulmonary fibrosis after lung transplantation","volume":"193","author":"ten Klooster","year":"2015","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.resinv.2012.12.002","article-title":"Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease","volume":"51","author":"Ando","year":"2013","journal-title":"Respir Invest"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib59","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.athoracsur.2015.06.024","article-title":"Influence of pulmonary hypertension on patients with idiopathic pulmonary fibrosis awaiting lung transplantation","volume":"101","author":"Hayes","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.chest.2024.04.025_bib60","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib61","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10554-020-02079-x","article-title":"Impairment of right ventricular strain evaluated by cardiovascular magnetic resonance feature tracking in patients with interstitial lung disease","volume":"37","author":"Kamide","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib62","first-page":"55","article-title":"Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study","volume":"16","author":"Takahashi","year":"2016","journal-title":"BMC Polm"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib63","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.21538","article-title":"Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease","volume":"54","author":"Trad","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.chest.2024.04.025_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104897","article-title":"Acute respiratory failure in critically ill patients with interstitial lung disease","volume":"9","author":"Zafrani","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.chest.2024.04.025_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141911","article-title":"Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias","volume":"10","author":"Hoeper","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.chest.2024.04.025_bib66","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/art.30423","article-title":"Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies","volume":"63","author":"Le Pavec","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.chest.2024.04.025_bib67","first-page":"A7127","article-title":"Forced vital capacity predicts outcome in scleroderma associated interstitial lung disease with concomitant pulmonary hypertension: data from the Pharos Registry","volume":"195","author":"Lee","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib68","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.transproceed.2018.10.018","article-title":"Influence of pulmonary hypertension on intrahospital mortality in lung transplantation for interstitial lung disease","volume":"51","author":"Corral-Blanco","year":"2019","journal-title":"Transplant Proc"},{"issue":"12","key":"10.1016\/j.chest.2024.04.025_bib69","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/thx.2006.068494","article-title":"Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation","volume":"62","author":"Mackay","year":"2007","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.chest.2024.04.025_bib70","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.transproceed.2020.02.120","article-title":"Secondary pulmonary hypertension among patients qualified for lung transplantation: single-center study","volume":"52","author":"Stacel","year":"2020","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.chest.2024.04.025_bib104","article-title":"Significance of pulmonary arterial pressure as a prognostic indicator in lung-dominant connective tissue disease. Research Support, Non-U.S","volume":"9","author":"Suzuki","year":"2014","journal-title":"Gov\u2019t. PLoS ONE."},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2019.06.033","article-title":"Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease","volume":"157","author":"Bax","year":"2020","journal-title":"Chest"},{"issue":"suppl 2","key":"10.1016\/j.chest.2024.04.025_bib106","first-page":"324","article-title":"The analysis of interstitial lung disease with pulmonary hypertension","volume":"16","author":"Shen","year":"2011","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pulmoe.2020.01.004","article-title":"Connective tissue disease-associated interstitial lung disease","volume":"28","author":"Oliveira","year":"2022","journal-title":"Pulmonology"},{"issue":"9","key":"10.1016\/j.chest.2024.04.025_bib108","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1159\/000515396","article-title":"Baseline characteristics and survival of an Australian interstitial pneumonia with autoimmune features cohort","volume":"100","author":"Jee","year":"2021","journal-title":"Respiration"},{"issue":"9","key":"10.1016\/j.chest.2024.04.025_bib109","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.healun.2019.06.015","article-title":"Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis. Multicenter Study","volume":"38","author":"Khawar","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.chest.2024.04.025_bib110","first-page":"741","article-title":"Lung Transplantation in Idiopathic Pulmonary Fibrosis: Risk Factors and Outcome","volume":"22","author":"Amor","year":"2020","journal-title":"Isr Med Assoc J"},{"issue":"suppl 4","key":"10.1016\/j.chest.2024.04.025_bib71","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1097\/00005344-198806124-00038","article-title":"Effects of 5\u00a0mg sublingual nitrendipine in patients with precapillary pulmonary hypertension due to pulmonary fibrosis","volume":"12","author":"Burger","year":"1988","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"suppl A","key":"10.1016\/j.chest.2024.04.025_bib72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/9.suppl_A.213","article-title":"Long-term reduction of pulmonary hypertension in interstitial lung fibrosis by isosorbide dinitrate","volume":"9","author":"Jezek","year":"1988","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.chest.2024.04.025_bib73","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1378\/chest.87.5.564","article-title":"Hemodynamic effect of hydralazine in interstitial lung disease patients with cor pulmonale. Immediate and short-term evaluation at rest and during exercise","volume":"87","author":"Lupi-Herrera","year":"1985","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib74","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1378\/chest.120.3.866","article-title":"Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension","volume":"120","author":"Preston","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.14423\/SMJ.0000000000000217","article-title":"Use of pulmonary arterial hypertension-specific therapy in non-WHO group I pulmonary hypertension","volume":"108","author":"Shujaat","year":"2015","journal-title":"South Med J"},{"issue":"9","key":"10.1016\/j.chest.2024.04.025_bib76","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1183\/09031936.97.10092051","article-title":"The effect of low-dose inhalation of nitric oxide in patients with pulmonary fibrosis","volume":"10","author":"Yoshida","year":"1997","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2024.04.025_bib77","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/resp.12294","article-title":"Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41512","volume":"73","author":"Chauvelot","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 57","key":"10.1016\/j.chest.2024.04.025_bib79","first-page":"1782","article-title":"Treatment of severe pulmonary hypertension in patients with interstitial lung disease: results in 72 patients from the \u201cHYPID\u201d prospective study","volume":"42","author":"Cottin","year":"2013","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2024.04.025_bib80","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib81","first-page":"82","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies","volume":"31","author":"Keir","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.chest.2024.04.025_bib82","first-page":"A4404","article-title":"Outcomes of treatment of pulmonary arterial hypertension in patients with interstitial lung disease","volume":"191","author":"Kim","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.healun.2007.11.576","article-title":"Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?","volume":"27","author":"Milman","year":"2008","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4 suppl","key":"10.1016\/j.chest.2024.04.025_bib84","doi-asserted-by":"crossref","first-page":"A2250","DOI":"10.1016\/j.chest.2020.08.1916","article-title":"Parenteral prostacyclin therapy in patients with pulmonary hypertension in the setting of interstitial lung disease","volume":"158","author":"Pfeifle","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib85","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211011329","article-title":"Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort study","volume":"11","author":"Saggar","year":"2021","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/thoraxjnl-2013-204150","article-title":"Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis","volume":"69","author":"Saggar","year":"2014","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib87","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1378\/chest.06-2101","article-title":"Sildenafil improves walk distance in idiopathic pulmonary fibrosis","volume":"131","author":"Collard","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2024.04.025_bib88","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1155\/2010\/686098","article-title":"Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease","volume":"17","author":"Mittoo","year":"2010","journal-title":"Can Respir J"},{"issue":"15","key":"10.1016\/j.chest.2024.04.025_bib89","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/eurheartj\/ehad005","volume":"44","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib90","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"issue":"25 suppl","key":"10.1016\/j.chest.2024.04.025_bib91","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib92","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"issue":"156","key":"10.1016\/j.chest.2024.04.025_bib93","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0009-2020","article-title":"BNP\/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?","volume":"29","author":"Lewis","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"5 pt 2","key":"10.1016\/j.chest.2024.04.025_bib94","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1600-6143.2006.01276.x","article-title":"Development of the new lung allocation system in the United States","volume":"6","author":"Egan","year":"2006","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib95","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01904-2018","article-title":"Diagnosis of pulmonary hypertension","volume":"53","author":"Frost","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib96","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1465-9921-14-6","article-title":"Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension","volume":"14","author":"Farha","year":"2013","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.chest.2024.04.025_bib97","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1183\/09031936.00152609","article-title":"A\u00a0simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis","volume":"36","author":"Nishiyama","year":"2010","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2024.04.025_bib98","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease: the ILD-GAP model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2024.04.025_bib99","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.chest.2021.04.037","article-title":"Incidence and prognostic significance of hypoxemia in fibrotic interstitial lung disease: an international cohort study","volume":"160","author":"Khor","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2024.04.025_bib100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12931-021-01790-0","article-title":"Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease","volume":"22","author":"Chen","year":"2021","journal-title":"Respir Res"},{"issue":"165","key":"10.1016\/j.chest.2024.04.025_bib101","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0087-2022","article-title":"The 6-min walk test as a primary end-point in interstitial lung disease","volume":"31","author":"Harari","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.chest.2024.04.025_bib102","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018764273","article-title":"Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension","volume":"8","author":"Yang","year":"2018","journal-title":"Pulm Circ"},{"issue":"8","key":"10.1016\/j.chest.2024.04.025_bib103","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","article-title":"Are surrogate markers adequate to assess cardiovascular disease drugs?","volume":"282","author":"Temple","year":"1999","journal-title":"JAMA"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224006615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224006615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T22:19:54Z","timestamp":1730326794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224006615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0012369224006615"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.04.025","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Hypertension in Interstitial Lung Disease","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}